Clinical Data Novartis reveals more data behind Pluvicto expansion bid PharmaphorumNovartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer.OncologyRead full story pharminent May 18, 2026 (Last updated: May 18, 2026) Pharmaphorum Novartis has reported new data to support its drive to expand the label of its radioligand therapy Pluvicto in prostate cancer. Oncology Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Regeneron immunotherapy combo comes up short in melanoma trialNext: AstraZeneca wins nod for blood pressure pill, opening new class of hypertension drugs Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
